As the life science industry moves from conventional biologics to advanced therapy medicinal products (ATMPs) such as cell and gene therapies, facilities must evolve to accommodate these new processes. Developers and life science companies may be wondering how to adapt their existing spaces and what an ideal facility looks like. FPBA’s Executive Vice President Andy Darragh provides insight on cell and gene therapy facility design.
